SCHEMBL3223358

SCHEMBL3223358

CN(C)c1ccc2c(c1)CCN(c1cccc(-c3cc(Nc4ccc(N5CCCCS5(=O)=O)cn4)c(=O)n(C)c3)c1CO)C2=O

nearest known ligand 0.76

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
BTK Q06187 19/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3212007 0.98 BTK (0.77) BTK
SCHEMBL3210553 0.90 BTK (0.85) BTK
SCHEMBL3203373 0.89 BTK (0.89) BTK
SCHEMBL3224514 0.89 BTK (0.79) BTK
SCHEMBL3208967 0.88 BTK (0.80) BTK
SCHEMBL3211994 0.87 BTK (0.69) BTK
SCHEMBL3212026 0.86 BTK (0.80) BTK
SCHEMBL3220285 0.86 BTK (0.83) BTK
SCHEMBL3217017 0.86 BTK (0.86) BTK
SCHEMBL3221165 0.86 BTK (1.00) BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683064-B2 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2010-03-23 US claimed
EP-2242749-B1 NOVEL PYRIDINONES AND PYRIDAZINONES HOFFMANN LA ROCHE (CH) 2013-04-10 EP disclosed
US-7906509-B2 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2011-03-15 US disclosed
US-7906509-B2 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2011-03-15 US disclosed
US-7906509-B2 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2011-03-15 US disclosed
US-20100099659-A1 Inhibitors of Bruton's Tyrosine Kinase KENNEDY-SMITH JOSHUA 2010-04-22 US disclosed
US-20100099659-A1 Inhibitors of Bruton's Tyrosine Kinase KENNEDY-SMITH JOSHUA 2010-04-22 US disclosed
US-20100099659-A1 Inhibitors of Bruton's Tyrosine Kinase KENNEDY-SMITH JOSHUA 2010-04-22 US disclosed
US-7683064-B2 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2010-03-23 US disclosed
US-7683064-B2 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2010-03-23 US disclosed
US-7683064-B2 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2010-03-23 US disclosed
US-20090306041-A1 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-12-10 US disclosed
US-20090306041-A1 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-12-10 US disclosed
US-20090306041-A1 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099659-A1 Inhibitors of Bruton's Tyrosine Kinase BTK, SYK, LYN BTK 1/4885
US-20090306041-A1 Inhibitors of Bruton's tyrosine kinase BTK, SYK, LYN BTK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.